Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery

Obesity Surgery
Peter RyeArya M Sharma

Abstract

Bariatric surgery is the most effective long-term treatment of severe obesity. Unfortunately, many patients experience inadequate weight loss, weight plateau, or weight recidivism. We sought to determine the efficacy of high-dose liraglutide (3.0 mg once daily) in patients with prior bariatric surgery. We performed a retrospective chart review of 33 consecutive patients, aged 18-65, who received liraglutide for weight loss in the setting of any previous bariatric surgery. Indications were weight recidivism (> 10% weight regain from lowest post-surgical weight), inadequate weight loss (< 20% weight loss from initial clinic assessment, or pre-surgical weight if unavailable), and plateau (patient desires further weight loss but does not fit into either other category). Our primary outcomes were median percentage weight loss and median BMI change at 16 and 28 weeks, inclusive of time taken to titrate the medication to target dose. Secondary outcomes were the presence of adverse effects and the need to discontinue the medication. Of a total of 33 patients identified, 20 met inclusion criteria and had adequate data to be included in our analysis. At 16 weeks median percentage weight loss was 7.1% (IQR 5.1-12.2%), and at 28 weeks 9.7%...Continue Reading

References

Oct 14, 2004·JAMA : the Journal of the American Medical Association·Henry BuchwaldKaren Schoelles
Jul 3, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T A WaddenUNKNOWN NN8022-1923 Investigators
Aug 6, 2013·Revista do Colégio Brasileiro de Cirurgiões·Denis PajeckiMarco Aurélio Santo
Sep 3, 2013·Obesity Surgery·Shahzeer KarmaliDaniel W Birch
Mar 29, 2014·Gastroenterology Research and Practice·C J de Gara, S Karmali
May 20, 2015·Clinical and Molecular Allergy : CMA·Carlo AgostiniEnrico Maggi
Jul 3, 2015·The New England Journal of Medicine·Xavier Pi-SunyerUNKNOWN SCALE Obesity and Prediabetes NN8022-1839 Study Group
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Melanie J DaviesRalph A DeFronzo
Oct 27, 2015·Pharmacotherapy·Wesley A Nuffer, Jennifer M Trujillo
Jun 4, 2016·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Juan J Gorgojo-MartínezClara Serrano-Moreno
Dec 18, 2016·Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery·Fatima Cody StanfordLouis J Aronne
Jul 8, 2017·International Journal of Obesity Supplements·B Laferrère

❮ Previous
Next ❯

Citations

Aug 10, 2019·International Journal of Clinical Practice·Juan J Gorgojo-MartínezFrancisca Almodóvar-Ruiz
Oct 4, 2019·Therapeutic Advances in Endocrinology and Metabolism·Alexis SudlowDimitri J Pournaras
Apr 16, 2020·Expert Opinion on Pharmacotherapy·Kishore M Gadde, Katelyn D Atkins
Oct 20, 2020·Gastrointestinal Endoscopy·Dilhana BadurdeenVivek Kumbhari
Feb 18, 2021·The Journal of Clinical Endocrinology and Metabolism·Karim KheniserSangeeta R Kashyap
Aug 24, 2021·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Nadia N AhmadHong Kan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Expert Review of Endocrinology & Metabolism
Alpana P ShuklaLouis J Aronne
Nature Reviews. Endocrinology
Jacqueline R Center, Chris P White
JAMA : the Journal of the American Medical Association
Amir A Ghaferi, Oliver A Varban
Proceedings of the American Philosophical Society
Harvey J Sugerman
© 2022 Meta ULC. All rights reserved